A Randomized, Controlled, Multicenter Clinical Study of Camrelizumab in Combination With Apatinib Mesylate and Chemotherapy Versus Camrelizumab Plus Chemotherapy in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
Latest Information Update: 25 Nov 2024
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary) ; Cisplatin; Paclitaxel
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 21 Nov 2024 Planned End Date changed from 1 Nov 2026 to 1 Mar 2027.
- 21 Nov 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Sep 2025.
- 24 Feb 2023 New trial record